Concerns Grow Over Side Effects from Unapproved Weight-Loss Drug Retatrutide
A leading obesity consultant has reported a concerning trend in hospitals, where an increasing number of patients are presenting with side effects from the weight-loss drug Retatrutide. This injectable peptide, currently undergoing clinical trials by Eli Lilly, has not received approval for human use anywhere globally and is illegal to sell in Ireland and other countries. Despite this, it has gained popularity, particularly among gym-goers looking to enhance their weight loss results. Professor Donal O'Shea highlighted the risks associated with its use, noting that personal trainers often recommend Retatrutide without providing adequate information about potential side effects. He recounted a recent case where a patient experienced severe vomiting and kidney issues after receiving the drug from a trainer at a gym. The most frequently reported side effects include gastrointestinal problems such as nausea, vomiting, diarrhea, and constipation, along with possible impacts on the liver, pancreas, and kidneys. Many patients do not disclose their use of Retatrutide, which complicates medical assessments and treatment. Shauna Louise Cleary, an online fitness coach, shared her experience of using Retatrutide before a gym photoshoot, describing severe adverse reactions that led her to stop using the drug. Eli Lilly has called for social media platforms to take action against the illegal sale of Retatrutide, and while some platforms have banned related advertisements, reports indicate that illegal sales continue. The Health Products Regulatory Authority has noted a rise in social media pages selling this unapproved drug. Professor O'Shea expressed deep concern over the trend, emphasizing the need for users to seek medical help if they experience adverse effects. He urged those using GLP-1s, including Retatrutide, to be open about their usage to ensure proper care and avoid further complications.




